ClinicalTrials.gg
Enrolling by invitationNCT06936527XS-03-II201Updated Sep 25, 2026

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

A Phase 1/2 interventional study of Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI and Drug: XS-03 in Colorectal Cancer and Metastatic Colorectal Cancer With RAS Mutation, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 1/2, Interventional, and Treatment

Updated Sep 25, 2026Eligibility revisedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Planned enrollment
73rd of 224
102 · median 63
Started
2025
with 12 others
Phase 1/2
11 of 230
5 open now
Primary completion
2028-04
later than 46 of 60 live
Registered
212th of 230
by date

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 73rd largest by planned enrollment of the 224 interventional ones that give a count, is one of 13 that started in 2025, is one of 11 in phase 1/2, reaches primary completion later than 46 of the 60 other live ones, and was the 212th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation

03

Conditions studied

  • Colorectal Cancer
  • Metastatic Colorectal Cancer With RAS Mutation
04

Who can participate

The criteria were revised on the registry on Sep 25, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the clinical trial and sign the form.
  2. Age ≥18 and ≤ 75 years. No gender restrictions.
  3. Patients with and/or cytologically confirmed colorectal cancer who are not suitable for surgical treatment.
  4. Advanced or metastatic colorectal cancer: Stage Ib patients must have received at least one prior systemic therapy; Stage II patients have no prior systemic therapy. For patients with previously /adjuvant therapy, disease progression must occur no less than 6 months after the end of therapy to be eligible for inclusion.
  5. Documentation of RAS mutation. The previously gene test report issued by qualified testing institution is acceptable. BRAF status is not restricted.
  6. Consent to provide tumor tissue samples and peripheral blood for biomarker analysis.
  7. Has measurable extracranial lesion according to v1.1 criteria, defined as at least one lesion that has not received radiotherapy. For previously radiotherapy lesion, there must be imaging evidence of progression after radiotherapy.
  8. (ECOG) performance status score 0-1.
  9. Expected ≥ 6 months.
  10. The patient has adequate hepatic, renal and bone marrow function.
  11. For a woman of must have a negative serum pregnancy test within 7 days prior to enrollment. Woman of child-bearing potential and fertile men must agree to use adequate for the duration of study participation and for 6 months after the last dose.

Exclusion criteria

Exclusion Criteria

  1. Patients with known high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) primary or colorectal cancer and suitable for treatment assessed by investigators.
  2. Previously received bevacizumab and its biosimilar therapy. (Only for phase II)
  3. Central nervous system metastases which are symptomatic or require therapy.
  4. Imaging shows major blood vessel invasion (such as the aorta, pulmonary artery, pulmonary vein, vena cava, etc.).
  5. Adverse events and/or complications that caused by previous antitumor therapy have not recovered to baseline level or ≤ grade 1.

    Baseline level or ≤ Grade 1. However, any grade of alopecia, pigmentation, or ≤ Grade 2 peripheral sensory neuropathy, or other conditions assessed by the investigator as having become chronic and not affecting the safety of the study medication are allowed for inclusion.

  6. With a history of other within 5 years or with other malignancies currently prior to screening, except colorectal cancer. Exception: curatively treated early-stage malignancies (in situ carcinoma or stage I tumors), such as adequately treated basal cell or squamous cell skin cancer or in situ cancer of the cervix.
  7. Patients have a significant risk of bleeding.
  8. Patients have a significant risk of thrombus.
  9. Patients have severe cardiovascular disease, including but not limited to: Ischemic heart disease within the past 6 months prior to screening; coronary artery disease post-surgery or stent implantation within 6 months; (NYHA) functional classification ≥ Class II within 6 months prior to screening; or known left ventricular insufficiency ( \<50%); or cerebrovascular accident within 6 months prior to screening; uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) despite standard treatment, or history of hypertensive crisis or hypertensive encephalopathy;severe arrhythmia requiring clinical intervention; any other cardiovascular disease that researchers regard the patient unsuitable for participation in the study.
  10. Patients with a significantly increased risk of prolongation.
  11. Patients unable to swallow drugs or have severe diseases that significantly affect drug absorption.
  12. Patients have one of the following viral active infections: active or C; (HIV) infection; active syphilis
  13. During screening, the presence of interstitial lung disease, interstitial pneumonia, pulmonary interstitial fibrosis requiring therapy, or a history of pneumonia caused by tyrosine kinase inhibitors.
  14. Patients received radiotherapy within the past 4 weeks prior to the first first dose of study drug.
  15. Patients received therapeutic surgeries (excluding diagnosis, , or drainage procedures) within the past 4 weeks prior to the first dose of study drug, including local treatments such as radiofrequency ablation for liver metastases, or are expected to have major surgeries during the study period.
  16. Severity infection need intravenous infusion of antibiotics, antiviral drugs, or hospitalisation within the past 2 weeks prior to the first dose of study drug.
  17. Patients must use strong inducers or inhibitors within the past 2 weeks prior to the first administration, or during the anticipated study period,
  18. History of severe allergy, or known allergy to any active or inactive components of the study drug product.
  19. Pregnancy or lactation.
  20. Patients with severe diseases of any organs or systems, any clinical or laboratory test abnormalities, or other reasons that investigator assess them unsuitable to participate in this clinical study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Experimental arm 1: XS-03 + FOLFOX/FOLFIRI + Bevacizumab

    Phase 1b: XS-03 escalating orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFOX or FOLFIRI and bevacizumab. FOLFOX (85 mg/m\^2 oxaliplatin, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m\^2 continuous intravenous infusion 5-FU) , 5 mg/kg bevacizumab FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m\^2 continuous intravenous infusion 5-FU), 5 mg/kg bevacizumab

    Biological: Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI

  • Experimental
    Experimental arm 2: XS-03 + FOLFOX/FOLFIRI + Bevacizumab

    Phase 2: XS-03 Recommended Phase 2 Dose (RP2D) and selected one more dosage orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combinationwith FOLFOX or FOLFIRI and bevacizumab. FOLFOX (85 mg/m\^2 oxaliplatin, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m\^2 continuous intravenous infusion 5-FU) , 5 mg/kg bevacizumab FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m\^2 continuous intravenous infusion 5-FU), 5 mg/kg bevacizumab

    Biological: Drug: XS-03

  • Active comparator
    Comparator: FOLFOX/FOLFIRI + Bevacizumab

    Phase 2: Comparator arm treat with FOLFOX or FOLFIRI + bevacizumab intravenously. FOLFOX (85 mg/m\^2 oxaliplatin, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m\^2 continuous intravenous infusion 5-FU) , 5 mg/kg bevacizumab FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m\^2 continuous intravenous infusion 5-FU), 5 mg/kg bevacizumab

    Biological: Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI

Interventions

  • BiologicalDrug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI

    Drug pages: Bevacizumab · Folfox protocol

    XS-03 orally Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously

  • BiologicalDrug: XS-03

    XS-03 orally

  • BiologicalBiological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI

    Drug pages: Bevacizumab · Folfox protocol

    Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of participants with Dose-limiting Toxicities (DLTs) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab

    Dose-limiting toxicities were defined as events related to XS-03 that were considered an adverse reaction or suspected adverse reaction during the first cycle of treatment

    Time frame: up to day 28

  2. Phase 1b: Determine the Maximum Tolerated Dose (MTD) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab

    MTD is defined as at most 1 patient out of 6 experiencing DLT

    Time frame: up to day 28

  3. Phase 2: Objective Response Rate (ORR) of two experimental arms and comparator arm

    Defined as the percentage of participants that achieve a best overall response of complete response (CR) or partial response (PR) (per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria)

    Time frame: up to 18 months after first dose of last patient

Secondary outcomes

  1. Phase 1b: Objective Response Rate (ORR) of all treated participants

    Time frame: up to 18 months after first dose of last patient

  2. Duration of response (DOR) of all treated participants

    Duration of response defined as time from when response was first documented until first documented disease progression or death, whichever occurs first.

    Time frame: up to 18 months after first dose of last patient

  3. Progression-free survival (PFS) of treated participants

    as determined based on RECIST version 1.1 criteria

    Time frame: up to 18 months after first dose of last patient

  4. Overall survival (OS) of treated participants

    Time in months from date of first dose for phase 1b and randomization for phase 2 to death due to any cause

    Time frame: up to 18 months after first dose of last patient

  5. Number of Participants With Adverse Events (AEs) of treated participants

    The severity of each AE will be graded using the Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: up to 28 days after last dose of study drug

  6. Number of Participants With Clinically Significant Change From Baseline in safety monitoring

    Time frame: up to 28 days after last dose of study drug

  7. Number of Participants With dose adjustment

    AE associated with dose reduction, interruption and discontinuation

    Time frame: up to 28 days after last dose of study drug

  8. Time to Reach Maximum Peak Plasma Concentration (Tmax)

    Pharmacokinetic parameter

    Time frame: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

  9. Maximum Plasma Concentration(Cmax)

    Pharmacokinetic parameter

    Time frame: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

  10. Area under the plasma concentration versus time curve from time zero to the last measurable concentration(AUC0-t)

    Pharmacokinetic parameter

    Time frame: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

  11. Elimination Half-life (T1/2)

    Pharmacokinetic parameter

    Time frame: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

  12. Systemic Clearance From Plasma Following Extravascular Administration (CL/F)

    Pharmacokinetic parameter

    Time frame: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

  13. The volume of distribution(Vd/F)

    Pharmacokinetic parameter

    Time frame: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

  14. Average concentration at steady state(Cavg,ss)

    Pharmacokinetic parameter

    Time frame: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

  15. Minimum observed concentration at steady state(Cmin,ss)

    Pharmacokinetic parameter

    Time frame: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Apr 2028, 35 months after the start.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 35 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2025
First posted
Apr 20, 2025
StartActual
May 23, 2025
Primary completionEst.
Apr 30, 2028
CompletionEst.
Jul 30, 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Maximum age 70 Years→75 Years; 1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAge ≥18 and ≤ 7075 years. No gender restrictions.
Exclusion criteria
  • EditedPatients have severe cardiovascular disease, including but not limited to: Ischemic heart disease within the past 6 months prior to screening; coronary artery disease post-surgery or stent implantation within 6 months; New York Heart Association (NYHA) functional classification ≥ Class II within 6 months prior to screening; or known left ventricular insufficiency (LVEF <50%);transient ischemic attack or cerebrovascular accident within 6 months prior to screening; uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) despite standard treatment, or history of hypertensive crisis or hypertensive encephalopathy;severe arrhythmia requiring clinical intervention; any other cardiovascular disease that researchers regard the patient unsuitable for participation in the study.
Sep 25, 2026
Sponsor
NovaOnco Therapeutics Co., Ltd.→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Eligibility Maximum age 70 Years→75 Years; 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAge ≥18 and ≤ 7075 years. No gender restrictions.
    Exclusion criteria
    • EditedPatients have severe cardiovascular disease, including but not limited to: Ischemic heart disease within the past 6 months prior to screening; coronary artery disease post-surgery or stent implantation within 6 months; New York Heart Association (NYHA) functional classification ≥ Class II within 6 months prior to screening; or known left ventricular insufficiency (LVEF <50%);transient ischemic attack or cerebrovascular accident within 6 months prior to screening; uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) despite standard treatment, or history of hypertensive crisis or hypertensive encephalopathy;severe arrhythmia requiring clinical intervention; any other cardiovascular disease that researchers regard the patient unsuitable for participation in the study.
    Sponsor NovaOnco Therapeutics Co., Ltd.→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06936527
Responsible party
Sponsor
First posted
Apr 20, 2025
Start date
May 23, 2025
Primary completion
Apr 30, 2028 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Sep 25, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Folfox protocol

Start the discussion